Abstract
The results of a recent phase 2 trial have shown that combined treatment with neratinib and capecitabine is active in patients with refractory HER2-positive breast cancer who have brain metastases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have